Anti‐CTLA‐4: Tremelimumab (3.5 or 10 mg/kg, per 4 weeks) was administered intravenously.Ablation: Radiofrequency or cryotherapy ablation was performed 36 days after initial ICI medication.TACE: Patients with Barcelona Clinic Liver Cancer (BCLC) Stage B received TACE in conjunction with ablation. This evidence concerns the gene CTLA4 and liver cancer.